These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17332569)

  • 1. Repeal law that puts "FDA on the payroll of the industry," says former NEJM editor.
    Kmietowicz Z
    BMJ; 2007 Mar; 334(7591):447. PubMed ID: 17332569
    [No Abstract]   [Full Text] [Related]  

  • 2. User fees to hasten FDA review.
    Gershon D
    Nature; 1992 Oct; 359(6396):567. PubMed ID: 1406982
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA user fee law poised for passage in Congress but not without stirring up controversy.
    Finkelstein J
    J Natl Cancer Inst; 2007 Jul; 99(14):1072-3. PubMed ID: 17623792
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 6. New drug law to speed scientific review.
    Nature; 1992 Oct; 359(6396):563. PubMed ID: 1406977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New law aims to distance the FDA from the drug industry.
    Lenzer J
    BMJ; 2005 May; 330(7500):1106. PubMed ID: 15891225
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA to collect fees from drug companies.
    Minn Med; 1992 Nov; 75(11):46. PubMed ID: 1435650
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug safety on trial.
    Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
    [No Abstract]   [Full Text] [Related]  

  • 10. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA user fees approved.
    Clin Pharm; 1993 Jan; 12(1):3. PubMed ID: 8428431
    [No Abstract]   [Full Text] [Related]  

  • 12. PDUFA reauthorization--drug safety's golden moment of opportunity?
    Hennessy S; Strom BL
    N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
    [No Abstract]   [Full Text] [Related]  

  • 13. New fee structure proposed by FDA might lead to more talk.
    Waters H
    Nat Med; 2011 Oct; 17(10):1159. PubMed ID: 21988966
    [No Abstract]   [Full Text] [Related]  

  • 14. New law broadens FDA safety authority, renews user fees.
    Fox JL
    Nat Biotechnol; 2007 Nov; 25(11):1189-90. PubMed ID: 17989653
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug safety special: the safety catch.
    Wadman M
    Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
    [No Abstract]   [Full Text] [Related]  

  • 16. US drug industry and FDA prepare for closer ties.
    Ashraf H
    Lancet; 2002 Jun; 359(9321):1923. PubMed ID: 12057560
    [No Abstract]   [Full Text] [Related]  

  • 17. Determinants of vaccine supply.
    Natl Bur Econ Res Bull Aging Health; 2011; (3):2-3. PubMed ID: 22207917
    [No Abstract]   [Full Text] [Related]  

  • 18. Playing "kick the FDA"--risk-free to players but hazardous to public health.
    Wood AJ
    N Engl J Med; 2008 Apr; 358(17):1774-5. PubMed ID: 18434649
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceuticals and medical devices: FDA oversight.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
    [No Abstract]   [Full Text] [Related]  

  • 20. US FDA seeks more pharmaceutical industry cash.
    Zwillich T
    Lancet; 2007 Feb; 369(9559):357. PubMed ID: 17283497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.